| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2013 | EP2545055A1 Imidazo [1, 2 -a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases |
| 01/16/2013 | EP2545054A1 Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
| 01/16/2013 | EP2545053A1 Azaisoquinolinone derivatives as nk3 antagonists |
| 01/16/2013 | EP2545052A1 Imidazopyridines syk inhibitors |
| 01/16/2013 | EP2545051A1 Compounds for the treatment of hepatitis c |
| 01/16/2013 | EP2545050A1 Compounds for the treatment of hepatitis c |
| 01/16/2013 | EP2545049A1 Crystalline salts of a potent hcv inhibitor |
| 01/16/2013 | EP2545047A1 Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| 01/16/2013 | EP2545046A1 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
| 01/16/2013 | EP2545045A1 Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| 01/16/2013 | EP2545044A1 Dabigatran etexilate-containing pharmaceutical composition |
| 01/16/2013 | EP2545042A1 Compounds for the treatment of hepatitis c |
| 01/16/2013 | EP2545038A1 Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 01/16/2013 | EP2545037A1 Inhibitors of protein kinases |
| 01/16/2013 | EP2545036A1 Bis aromatic compounds for use as ltc4 synthase inhibitors |
| 01/16/2013 | EP2545033A2 Propionic acids, propionic acid esters, and related compounds |
| 01/16/2013 | EP2545027A1 Crystalline salts and/or cocrystals of o-desmethyltramadol |
| 01/16/2013 | EP2545025A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 01/16/2013 | EP2544768A1 Anti-cancer agent delivery vehicles capable of improved laoding |
| 01/16/2013 | EP2544720A1 Carbohydrate-polyamino acid-drug conjugates |
| 01/16/2013 | EP2544703A2 Methods of treating vascular inflammatory disorders |
| 01/16/2013 | EP2544699A2 A novel method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer |
| 01/16/2013 | EP2544696A1 Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders |
| 01/16/2013 | EP2544695A1 Sterile alginate-based aqueous composition for medical use and process for the preparation thereof |
| 01/16/2013 | EP2544694A2 A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit c5 interactions with properdin |
| 01/16/2013 | EP2544693A1 A novel mucosal vaccination approach for herpes simplex virus type-2 |
| 01/16/2013 | EP2544692A1 Use of tigecycline for treatment of cancer |
| 01/16/2013 | EP2544691A2 Compound, composition, and method for protecting skin from high energy visible light |
| 01/16/2013 | EP2544690A2 Arylvinylazacycloalkane compounds for constipation |
| 01/16/2013 | EP2544689A2 Solid compositions |
| 01/16/2013 | EP2544688A2 Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| 01/16/2013 | EP2544687A1 Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| 01/16/2013 | EP2544686A2 Combination methods for treatment of disease |
| 01/16/2013 | EP2544685A2 Solid pharmaceutical composition, comprising donepezil hydrochloride of the crystalline polymorphous form i |
| 01/16/2013 | EP2544684A1 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (dpp-1) |
| 01/16/2013 | EP2544683A2 Synergistic effect of tocotrienols and curcumin |
| 01/16/2013 | EP2544682A1 Phytocannabinoids in the treatment of cancer |
| 01/16/2013 | EP2544681A1 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation |
| 01/16/2013 | EP2544680A2 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| 01/16/2013 | EP2544679A1 Pde10 inhibitors and related compositions and methods |
| 01/16/2013 | EP2544678A2 Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dubé syndrome |
| 01/16/2013 | EP2544677A2 Beta -adrenergic receptor agonists and uses thereof |
| 01/16/2013 | EP2544676A1 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas |
| 01/16/2013 | EP2544675A1 Antioxidant composition for reducing oxidative stress ascribable to the treatment with hormonal contraceptive drugs |
| 01/16/2013 | EP2544674A1 Cdc7 kinase inhibitors and uses thereof |
| 01/16/2013 | EP2544673A1 Thioxanthone-based autophagy inhibitor therapies to treat cancer |
| 01/16/2013 | EP2544672A1 Combination anti-cancer therapy |
| 01/16/2013 | EP2544671A2 Pharmaceutical composition for the treatment of chlamydial infection |
| 01/16/2013 | EP2544669A1 Adhesive patch for therapeutic agent delivery |
| 01/16/2013 | EP2544663A2 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| 01/16/2013 | EP2544662A2 Foamable formulation |
| 01/16/2013 | EP2544660A2 Rifaximin ready-to-use suspension |
| 01/16/2013 | EP2544659A2 Highly permeating terbinafine formulation for treating onychomycosis |
| 01/16/2013 | EP2544657A2 The use of amisulpride as an anti-emetic |
| 01/16/2013 | EP2544555A1 Compositions for masking the flavor of nutrients and methods for making same |
| 01/16/2013 | EP2544543A1 Method of treatment |
| 01/16/2013 | EP2544542A1 Analgesic compounds, compositions, and uses thereof |
| 01/16/2013 | EP2544541A1 Combination therapy for treating breast cancer |
| 01/16/2013 | EP2544540A1 Lenalidomide and thalidomide immunoassays |
| 01/16/2013 | EP2544539A1 Maternal sialic acid supplementation |
| 01/16/2013 | EP2544538A1 High-purity steviol glycosides |
| 01/16/2013 | EP2544537A1 Parenteral formulations of macrolide antibiotics |
| 01/16/2013 | EP2544536A1 Fatty acid conjugates of quetiapine, process for making and using the same |
| 01/16/2013 | EP2544535A1 Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase |
| 01/16/2013 | EP2544534A1 Compositions, methods, and devices for the treatment of dysmenorrhea |
| 01/16/2013 | EP2281822B1 New dihydroindolone derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/16/2013 | EP2014304B1 Colon cleansing compositions |
| 01/16/2013 | CN1968686B Guanylhydrazone salts, compositions, processes of making and methods of using |
| 01/16/2013 | CN1863513B Abuse-proofed dosage form |
| 01/16/2013 | CN1838954B Glycogen synthase kinase-3 inhibitors |
| 01/16/2013 | CN1763056B Nucleotide analog compound |
| 01/16/2013 | CN102884075A Method for inhibiting HIV replication in mammal and human cells |
| 01/16/2013 | CN102884072A Substituted androst-4-ene diones |
| 01/16/2013 | CN102884067A Prophylactic or therapeutic medication for inner ear disorders |
| 01/16/2013 | CN102884066A Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| 01/16/2013 | CN102884065A Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| 01/16/2013 | CN102884064A Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
| 01/16/2013 | CN102884063A Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators |
| 01/16/2013 | CN102884062A Aminopyrimidine kinase inhibitors |
| 01/16/2013 | CN102884060A Heterocyclic compounds useful for kinase inhibition |
| 01/16/2013 | CN102884059A N-酰基环胺衍生物或其可药用盐 N- acyl cyclic amine derivative or pharmaceutically acceptable salt thereof |
| 01/16/2013 | CN102884058A 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts |
| 01/16/2013 | CN102884057A 雄激素受体调节剂及其用途 Androgen receptor modulators and their use |
| 01/16/2013 | CN102884056A Ketobenzofuran derivatives, method for synthesising same, and intermediates |
| 01/16/2013 | CN102884053A Cyclopropanecarboxylic acid derivative |
| 01/16/2013 | CN102884052A Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
| 01/16/2013 | CN102884051A Pyrazole compounds as CRTH2 antagonists |
| 01/16/2013 | CN102884049A Heterocyclic amides as ROCK inhibitors |
| 01/16/2013 | CN102884048A Amino-heteroaryl derivatives as HCN blockers |
| 01/16/2013 | CN102884047A 2-pyridone compounds |
| 01/16/2013 | CN102884044A Derivatives of aminoindanes, their preparation and their application in therapeutics |
| 01/16/2013 | CN102884037A Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 01/16/2013 | CN102884035A Synthesis of magnolol and its analogue compounds |
| 01/16/2013 | CN102883733A AGE production inhibitor |
| 01/16/2013 | CN102883732A Compositions comprising extracts of southernwood and an amine compound |
| 01/16/2013 | CN102883728A Sulodexide for use in the treatment of pathologies wherein metalloproteinases are involved |
| 01/16/2013 | CN102883727A Materials and methods for prevention and treatment of viral infections |
| 01/16/2013 | CN102883726A Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2 -thienylmethylbenzene derivatives as inhibitors of SGLT |
| 01/16/2013 | CN102883725A Topical pharmaceutical compositions comprising mometasone furoate |
| 01/16/2013 | CN102883724A Use of meloxicam for the long-term treatment of kidney disorders in cats |